Stakeholders urge FDA to update CGT regulations to ease path to market for promising therapies
Regulatory NewsFerdous Al-Faruque
Biologics/ biosimilars/ vaccinesCBERHuman cells, tissues, and cellular and tissue-based products (HCT/Ps)Regulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)